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MaBACKGROUND Excessive myocardial collagen cross-linking (CCL) determines myocardial collagen’s resistance to
degradation by matrix metalloproteinase (MMP)-1 and interstitial accumulation of collagen ﬁbers with impairment of
cardiac function.
OBJECTIVES This study sought to investigate whether CCL and a newly identiﬁed biomarker of this alteration are
associated with hospitalization for heart failure (HHF) or cardiovascular death in patients with HF and arterial hyper-
tension in whom other comorbidities were excluded.
METHODS Endomyocardial biopsies and blood samples from 38 patients (invasive study), and blood samples from 203
patients (noninvasive study) were analyzed. Mean follow-ups were 7.74  0.58 years and 4.72  0.11 years, respectively.
Myocardial CCL was calculated as the ratio between insoluble and soluble collagen. The ratio between the C-terminal
telopeptide of collagen type I (CITP) and matrix metalloproteinase-1 (CITP:MMP-1) was determined in blood samples.
RESULTS Invasive study: CCL was increased (p < 0.001) in patients compared with controls. Patients were categorized
according to normal or high CCL values. Patients with high CCL exhibited higher risk for subsequent HHF (log-rank test
p ¼ 0.022), but not for cardiovascular death. CITP:MMP-1 was inversely associated with CCL (r ¼ 0.460; p ¼ 0.005) in
all patients. Receiver operating characteristic curves rendered a CITP:MMP-1 cutoff #1.968 (80% sensitivity and 76%
speciﬁcity) for predicting high CCL. Noninvasive study: Patients were categorized according to CITP:MMP-1 ratio values as
normal ratio (>1.968) or low ratio (#1.968). Patients with a low ratio exhibited higher risk for HHF (log-rank test
p ¼ 0.014), which remained signiﬁcant after adjustment for relevant covariables (adjusted hazard ratio: 2.22; 95% CI:
1.37 to 3.59, p ¼ 0.001). In addition, CITP:MMP-1–based categorization yielded signiﬁcant integrated discrimination
and net reclassiﬁcation improvements (p ¼ 0.003 and p ¼ 0.009, respectively) for HHF over relevant risk factors.
CITP:MMP-1 was not associated with the risk of cardiovascular death.
CONCLUSIONS Excessive myocardial CCL is associated with HHF in hypertensive patients with HF. In this popu-
lation, the serum CITP:MMP-1 ratio identiﬁes patients with increased CCL and high risk of HHF. (J Am Coll Cardiol
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ABBR EV I A T I ON S
AND ACRONYMS
CCL = collagen cross-linking
CI = conﬁdence interval
CITP = C-terminal telopeptide
of collagen type I
CVF = collagen volume fraction
DM = diabetes mellitus
HF = heart failure
HHF = hospitalization for heart
failure
IDI = integrated discrimination
improvement
IHD = ischemic heart disease
LV = left ventricle/ventricular
LVEF = left ventricular ejection
fraction
MMP = matrix
metalloproteinase
NRI = net reclassiﬁcation index
NT-proBNP = N-terminal pro–
B-type natriuretic peptide
ROC = receiver-operating
characteristic
TIMP = tissue inhibitor of
matrix metalloproteinases
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252D ue to its adverse consequences onleft ventricular (LV) mechanicsand function, electrical activity,
and coronary microcirculation, myocardial
ﬁbrosis is involved in the pathophysiology
and clinical course of heart failure (HF) of
different etiologies (1). For instance, myocar-
dial ﬁbrosis, evaluated on biopsy samples
and quantitatively deﬁned by the increase
in volume of myocardial tissue occupied by
collagen ﬁbers (namely, collagen type I), is
associated with increased LV stiffness and
diastolic dysfunction (2), impaired LV
contraction and systolic dysfunction (3), and
long-term mortality (4,5) in treated HF
patients.SEE PAGE 261As demonstrated in different experimental
models of pressure overload, myocardial
ﬁbrosis is characterized, not only by exces-
sive deposition of collagen ﬁbers, but also by
increased cross-linking of collagen ﬁbrils
within the ﬁbers (i.e., collagen cross-linking
[CCL]) (6–8). CCL is a process whereby
collagen ﬁbrils are covalently linked to oneanother by the enzyme lysyl oxidase (LOX), thus
forming insoluble ﬁbers with increased thickness and
material stiffness (9). In addition, CCL determines the
resistance of collagen ﬁbers to degradation by matrix
metalloproteinase (MMP)-1 (10), resulting in dimin-
ished cleavage of a small C-terminal telopeptide of
the ﬁber (CITP in the case of collagen type I ﬁbers,
where it represents 1 of the 2 major cross-link sites)
and a large amino-terminal telopeptide.
Although recent clinical studies point to an excess
of CCL as a major determinant of LV diastolic and
systolic dysfunction in patients with HF (2,11,12), no
information on its prognostic signiﬁcance in these
patients is available. We therefore hypothesized that
an excess of myocardial CCL is associated with long-
term outcomes in patients with chronic HF attribut-
able to hypertension. We also hypothesized that a
diminished circulating level of CITP (corrected by
total or unbound MMP-1 availability) may be a
biomarker of reduced collagen type I degradation due
to increased CCL. To test these hypotheses, in an
invasive study, the association of myocardial CCL with
clinical outcomes (i.e., hospitalization for heart failure
[HHF] and cardiovascular death) andwith CITP:MMP-1
and CITP:(MMP-1: tissue inhibitor of matrix metal-
loproteinase 1 [TIMP-1]) ratios were analyzed in a
small cohort of patients with HF of hypertensive eti-
ology. In a noninvasive study, associations betweenthe CITP:MMP-1 ratio and the same clinical outcomes
were analyzed in another larger cohort of patients
with HF of hypertensive etiology.
METHODS
All of the subjects gave written informed consent to
participate in the study, and the institutional review
committee approved the study protocol. The study
conformed to the principles of the Helsinki
Declaration.
STUDY SUBJECTS. Patients were consecutively
enrolled between 2002 and 2010. The patient popu-
lation of the invasive and the noninvasive studies
consisted of 38 and 203 hypertensive patients with a
previous clinical diagnosis of chronic stage C HF,
respectively. None of the patients exhibited ischemic
heart disease (IHD), diabetes mellitus (DM), or stages
3 to 5 chronic kidney disease (CKD). Blood samples
from the coronary sinus and the antecubital vein, and
3 transvenous endomyocardial biopsies from the
middle area of the interventricular septum were
taken from each invasive study patient during a car-
diac catheterization procedure. Blood samples from
the antecubital vein were taken in each patient from
the noninvasive study.
Septal endomyocardial biopsies were obtained
from autopsies of 10 age- and sex-matched subjects
with no macroscopic and microscopic cardiac lesions
to assess control reference values for histomorpho-
logical myocardial parameters. For further details,
see the Online Appendix.
CARDIAC AND BIOCHEMICAL STUDIES. Two-
dimensional echocardiographic, pulsed Doppler, and
tissue Doppler imaging were performed in all patients.
LV mass and dimensions, and parameters assessing
systolic and diastolic function were measured. For
further details, see the Online Appendix.
Plasma N-terminal pro–B-type natriuretic peptide
(NT-proBNP), and serum CITP, MMP-1, and TIMP-1
were measured by enzyme-linked immunosorbent
assay methods in all patients. CITP, MMP-1, and
TIMP-1 values were expressed in molarity and
CITP:MMP-1 and CITP:(MMP-1/TIMP-1) ratios were
calculated in each patient. For further details, see the
Online Appendix.
HISTOMORPHOLOGICAL STUDIES. To assess myocar-
dial ﬁbrosis, the fraction of myocardial volume
occupied by collagen ﬁbers or collagen volume
fraction (CVF) was determined by morphometry in
sections stained with collagen-speciﬁc picrosirius
red. Immunohistochemical analysis of collagen
types I and III was performed on formalin-ﬁxed,
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253parafﬁn-embedded sections. The fraction of myocar-
dial volume with positive staining for either collagen
type I or collagen type III ﬁbers (CIVF and CIIIVF,
respectively) was analyzed by morphometry.
To distinguish between cross-linked or insoluble
collagen and non–cross-linked or soluble collagen,
colorimetric and enzymatic procedures were used
(13,14). The concentration of each form of collagen
was corrected by the total amount of protein. CCL was
calculated as the ratio between the insoluble and
soluble collagen. For further details, see the Online
Methods.
STUDY OUTCOME. The primary outcome was ﬁrst
HHF after enrollment and was identiﬁed by medical
record review. HHF was deﬁned as worsening signs
and symptoms of HF that required urgent therapy
and resulted in hospitalization (15). The secondary
outcome was death from cardiovascular causes (i.e.,
congestive HF, acute myocardial infarction, malig-
nant arrhythmias, sudden death, stroke, cardiorespi-
ratory arrest). Vital status was ascertained by Social
Security Medical Registries, and in the cases where
any patient failed to appear at the scheduled review,
his/her relatives were contacted by phone. Two
board-certiﬁed cardiologist investigators blinded to
the patients’ histomorphological and biochemical
data adjudicated outcomes according to the
pre-speciﬁed criteria.
STATISTICAL ANALYSIS. Values are expressed as
mean  SEM and 95% conﬁdence interval (CI), and
categorical variables are expressed as numbers and
percentages. Invasive study patients were catego-
rized in 2 subgroups according to values of myocar-
dial CCL within (subgroup with normal CCL) and
above (subgroup with high CCL) the upper limit of
normality (established as mean þ 1.96 SD obtained in
control subjects and equal to 2.96). To analyze dif-
ferences between patients from the 2 subgroups in
the invasive study, a Student t test for unpaired data
was performed once normality was demonstrated
(Shapiro-Wilks test); otherwise, a nonparametric test
(Mann-Whitney U test) was used. Categorical vari-
ables were analyzed by the chi-square test or Fisher
exact test, when necessary. The correlation between
continuously distributed variables was tested using
the Pearson and Spearman correlation coefﬁcients
and univariate regression analysis.
Receiver-operating characteristic (ROC) curves
allowed determination of the overall performance of
CITP:MMP-1 and CITP:(MMP-1:TIMP-1) ratios deter-
mined in antecubital vein blood for identifying
abnormally high CCL in the invasive study patient
population. The cutoff point (1.968) established byROC analysis for the CITP:MMP-1 ratio in the invasive
study was used to categorize patients from the
noninvasive study into 2 subgroups: those with
values >1.968 (normal CITP:MMP-1 ratio) and those
with values #1.968 (low CITP:MMP-1 ratio).
Although these studies were originally designed as
case-control studies, the percentages of patients free
of the considered outcomes were estimated by the
Kaplan-Meier method; unadjusted differences were
assessed with log-rank tests. Only the ﬁrst outcome
was considered for the analysis and patients without
an outcome were censored at the date of their last
follow-up. Multiple Cox regression analysis was used
to calculate hazard ratios and corresponding 95% CIs
for the risk of future outcomes, adjusting for relevant
covariables. In the invasive study, the covariables
selected were peak early velocity of the transmitral
ﬂow divided by the peak early diastolic velocity of the
mitral annulus displacement (E:E0) ratio, LV ejection
fraction (LVEF), and NT-proBNP. In the noninvasive
study, covariables were selected by forward stepwise
Cox regression analysis, retaining those covariables
that remained signiﬁcant at p < 0.05 (systolic blood
pressure, estimated glomerular ﬁltration rate, LV
mass index, LVEF, NT-proBNP, and treatment with
beta-blockers and with calcium antagonists), along
with age and sex. Backward stepwise analysis yielded
the same 7 covariables. The proportional hazard
assumption was veriﬁed using Schoenfeld’s residuals.
Finally, to estimate the ability of the CITP:MMP-1
ratio-based classiﬁcation to improve risk prediction
in the noninvasive study, we calculated the inte-
grated discrimination improvement (IDI) and the
continuous net reclassiﬁcation index (NRI). We pre-
dicted in each subject the risk for outcomes from a
Cox regression basic model or the basic model
extended with the predictor variable (categorization
by level of the CITP:MMP-1 ratio > or #1.968), and the
continuous NRI and IDI were calculated as described
by Pencina et al. (16).
Statistical analyses were performed using SPSS
(version 15.0, SPSS, Armonk, New York) and STATA
(version 12.1, Stata Corp., College Station, Texas). NRI
and IDI were calculated with the help of a STATA
add-on (17).
RESULTS
INVASIVE STUDY. Class iﬁcat ion of pat ients on
the bas i s of CCL. CCL was increased (p < 0.001)
in the whole group of patients compared with con-
trols (3.31  0.14 vs. 1.43  0.29). Taking into
account the criteria mentioned previously (Methods
section, Statistical Analysis subsection), 11 patients
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254exhibited normal CCL values (subgroup with normal
CCL 2.30  0.11) and 27 patients exhibited high CCL
values (subgroup with high CCL 3.73  0.13). The
clinical and echocardiographic characteristics of the 2
patient subgroups are shown in Online Table 1. No
differences in histologically assessed collagen tissue
were observed between patients with normal and
high CCL (CVF: 7.21  0.75% vs. 7.64  0.63%;
CIVF:CIIIVF ratio: 7.62  1.83 vs. 6.71  0.84).
The CITP:MMP-1 ratio was reduced in patients with
high CCL, compared with patients with normal CCL, in
both coronary sinus blood (1.38  0.15 vs. 1.77  0.15,
p ¼ 0.026) and antecubital vein blood (1.61  0.14
vs. 2.83  0.35, p ¼ 0.006) (Figure 1). In addition, the
CITP:(MMP-1:TIMP-1) ratio was lower in patients with
high CCL than in patients with normal CCL in both
coronary sinus blood (79.04  10.17 vs. 111.55  14.21,
p¼ 0.043) and antecubital vein blood (79.96  8.84 vs.
142.17  20.24, p ¼ 0.009) (Figure 1).
CCL was directly correlated with E:E0 (r ¼ 0.625,
p < 0.001) and inversely correlated with LVEF
(r ¼0.430, p ¼ 0.007) in all patients. In addition, CCL
was directly correlated with NT-pro-BNP (r ¼ 0.421,
p ¼ 0.010) in all patients. Inverse correlations were
found between the CITP:MMP-1 ratio in antecubital
vein blood and myocardial CCL (r ¼0.460, p ¼ 0.005)
(Figure 2) and insoluble collagen (r ¼ 0.452,
p ¼ 0.006), and between the CITP:(MMP-1:TIMP-1)FIGURE 1 Distribution of Potential Circulating Biomarkers of CCL in
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antecubital vein in patients with normal or high myocardial CCL, as deﬁ
telopeptide of collagen type I; HF ¼ heart failure; MMP ¼ matrix metalratio in antecubital vein blood and myocardial CCL
(r ¼ 0.387, p ¼ 0.022) (Figure 2) and insoluble
collagen (r ¼ 0.425, p ¼ 0.011) in all patients.
Analys i s of ROC curves . The ROC curves allowed
for the determination of the overall performance of
serum CITP:MMP-1 and CITP:(MMP-1:TIMP-1) ratios
determined in antecubital vein blood for identiﬁca-
tion of high myocardial CCL in HF patients. The area
under the ROC curve was similar for the CITP:MMP-1
ratio and the CITP:(MMP-1:TIMP-1) ratio (Figure 3,
Table 1), and both curves were higher than 0.50
(Table 1). From the ROC curves, cutoff reference
values for serum CITP:MMP-1 and CITP:(MMP-1:
TIMP-1) ratios were calculated. The sensitivity and
speciﬁcity of each of these 2 values for identifying
high CCL are presented in Table 1. Overall, the cutoff
value of the serum CITP:MMP-1 ratio showed better
speciﬁcity and sensitivity. This parameter was
therefore chosen as a potential biomarker of
myocardial CCL.
Fol low-up and outcomes . The mean follow-up in
patients with normal and high CCL was 9.48  1.08
years (range 0.72 to 12.05 years) and 7.22  0.65 years
(range: 1.19 to 11.39 years), respectively. Two patients
(18%) with normal CCL presented with HHF, as
compared with 17 patients (63%) with high CCL
(chi-square test p ¼ 0.012; log-rank test p ¼ 0.022).
Multivariate Cox regression analysis, including thePatients With HF of Hypertensive Etiology From the Invasive Study
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FIGURE 2 Association of Potential Circulating Biomarkers of CCL With Myocardial CCL in Patients With HF of Hypertensive Etiology
From the Invasive Study
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Inverse correlations between the serum ratio of CITP to total MMP-1 (CITP:MMP-1) (y ¼ 0.43x þ 4.14) (left panel) and the serum ratio of CITP
to unbound MMP-1 [CITP:(MMP-1:TIMP-1)] (y ¼ 0.006x þ 3.86) (right panel) determined in blood from the antecubital vein and myocardial
collagen cross-linking in all patients. Abbreviations as in Figure 1.
FIGURE 3 ROC Curves for Determining Abnormally High Myocardial CCL
in the Invasive Study
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abbreviations as in Figure 1.
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255covariables E:E0 ratio, LVEF, and NT-proBNP, showed
a signiﬁcantly increased risk of HHF for patients with
high CCL, as compared with patients with normal
CCL, with a hazard ratio of 5.42 (95% CI: 1.11 to 26.37,
p ¼ 0.036). Additional adjustments were not consid-
ered because of the low number of patients. A total of
2 deaths (18%) in the subgroup with normal CCL and 9
(33%) in the subgroup with high CCL were due to
cardiovascular causes (chi-square test p ¼ 0.350; log-
rank test p ¼ 0.292).
NONINVASIVE STUDY. Class iﬁcat ion of pat ients
on the bas i s of the C ITP :MMP-1 rat io . Taking into
account the criteria mentioned previously (Methods
section, Statistical Analysis subsection), patients in
this study were classiﬁed into 2 subgroups: those with
CITP:MMP-1 ratio values >1.968, predicting a normal
myocardial CCL (subgroup with normal CITP:MMP-1
ratio n ¼ 89) and patients with CITP:MMP-1 ratio
values #1.968, predicting high myocardial CCL (sub-
group with low CITP:MMP-1 ratio n ¼ 114). Clinical
and echocardiographic characteristics of the 2 patient
subgroups are shown in Online Table 2.
Fol low-up and outcomes. The mean follow-up in
patients with normal and low CITP:MMP-1 ratios was
4.58  0.18 years (range: 0.38 to 6.60 years) and 4.84 
0.14 years (range 0.24 to 7.21 years), respectively.
Thirty patients (34%) with normal CITP:MMP-1 ratios
presented with HHF, as compared with 62 patients
FIGURE 4 Kaplan-
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TABLE 1 Overall Performance of the 2 Serum Parameters for
Predicting High Myocardial CCL According to ROC Curves
Serum CITP:MMP-1
Ratio
Serum CITP:(MMP-1:TIMP-1)
Ratio
AUC 0.798 0.724
95% CI 0.648–0.948 0.560–0.887
p Value 0.004 0.032
Cutoff 1.968 94.83
Sensitivity, % 80 73
Speciﬁcity, % 76 67
Chi-square test 8.61 5.30
p Value 0.003 0.021
AUC ¼ area under the curve; CCL ¼ collagen cross-linking; CI ¼ conﬁdence
interval; CITP ¼ C-terminal telopeptide of collagen type I; MMP-1 ¼ matrix
metalloproteinase-1; ROC ¼ receiver-operating characteristic; TIMP-1 ¼ tissue
inhibitor of MMP-1.
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256(54%) with low CITP:MMP-1 ratios (chi-square test
p ¼ 0.003). Longitudinal analysis performed by
Kaplan-Meier curves showed that patients with low
CITP:MMP-1 ratios had a higher risk of HHF than pa-
tients with normal CITP:MMP-1 ratios (log-rank test
p ¼ 0.014) (Figure 4). Multivariate Cox regressionMeier Curves for HHF in the Noninvasive Study
Subgroups
P=0.014
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eier analysis and log-rank test show the percentage of patients free
P:MMP-1 ratio, patients with values of the serum ratio of C-terminal
en type I [CITP] to total matrix metalloproteinase-1 [MMP-1] >1.968,
P-1 ratio, patients with CITP:MMP-1 ratio values #1.968, n ¼ 114).
rmined in blood from the antecubital vein. HHF ¼ hospitalization for
bbreviations as in Figure 1.analysis, including relevant covariables (age, sex,
systolic blood pressure, estimated glomerular ﬁltra-
tion rate, LV mass index, LVEF, NT-proBNP and treat-
ment with beta-blockers and calcium antagonists),
showed a signiﬁcantly increased risk of HHF for
patients with low CITP:MMP-1 ratios, as compared
with patients with normal CITP:MMP-1 ratios, with a
hazard ratio of 2.22 (95% CI: 1.37 to 3.59, p ¼ 0.001).
A total of 15 (17%) deaths in the subgroup with normal
CITP:MMP-1 ratio and 22 (19%) in the subgroup
with low CITP:MMP-1 ratio were due to cardiovas-
cular causes (chi-square test p ¼ 0.654; log-rank test
p ¼ 0.935).
Improvement of r i sk pred ict ion . IDI and contin-
uous NRI analyses indicated that addition of the
categorical variable CITP:MMP-1 ratio #1.968 to a
model that included the previously mentioned rele-
vant covariables improved risk prediction of HHF,
although it did not inﬂuence risk of death from
cardiovascular causes (Table 2).
DISCUSSION
The novelty of our study is that we report indepen-
dent associations between an excess of myocardial
CCL and HHF in a cohort of patients with HF of hy-
pertensive etiology. In addition, we describe, for the
ﬁrst time, that the serum CITP:MMP-1 ratio associates
with myocardial CCL in the same cohort of patients
and predicts the risk of HHF in an independent, larger
cohort of patients with HF of hypertensive etiology.
Furthermore, we prove the incremental prognostic
value of this ratio over important risk factors, as
conﬁrmed by 2 measures of improvement in
discrimination: IDI and continuous NRI.
ASSOCIATION OF MYOCARDIAL CCL WITH THE RISK
OF HHF. We found that approximately two-thirds of
patients with HF of hypertensive etiology exhibit
high CCL. Of interest, compared with patients with
normal CCL, patients with high CCL exhibited more
severe LV diastolic and systolic dysfunction, but
similar CVF and CIVF:CIIIVF ratio. These ﬁndings
suggest that an altered organization of the collagen
ﬁbril to form the collagen ﬁber may be more deter-
minant than the amount of ﬁbers per se in the detri-
mental impact of myocardial ﬁbrosis on LV function
in HF patients of hypertensive etiology.
To the best of our knowledge, this is the ﬁrst report
to demonstrate the prognostic impact of myocardial
CCL in HF patients. In particular, high CCL was
associated with increased risk of HHF in patients with
HF of hypertensive etiology. Under a pathophysio-
logical point of view, it can be argued that high
myocardial CCL may reduce diastolic reserve and
TABLE 2 IDI and NRI for Outcomes by Adding the Serum CITP:MMP-1 Ratio to a Model
Including Covariables
Outcome Variable
IDI NRI
IDI (%) 95% CI p Value NRI (%) 95% CI p Value
Hospitalization for HF 5.07 1.70 to 8.44 0.003 38.7 9.50 to 67.9 0.009
Death from cardiovascular
causes
0.46 1.05 to 3.93 0.55 11.2 26.5 to 48.8 0.56
The IDI is the difference between the discrimination slopes of basic models (including age, sex, systolic blood
pressure, estimated glomerular ﬁltration rate, LV mass index, LVEF, NT-proBNP, and treatment with beta-
blockers and calcium antagonists) and basic models extended with the predictor variable. The discrimination
slope is the difference in predicted probabilities (%) between patients with and without event. The NRI reﬂects
the improvement in discriminative power by adding the serum CITP:MMP-1 ratio (cutoff ¼ 1.968) to a model
already including relevant covariables (see above).
HF ¼ heart failure; IDI ¼ integrated discrimination improvement; LV ¼ left ventricular; LVEF ¼ left ventricular
ejection fraction; NRI ¼ net reclassiﬁcation improvement; NT-proBNP ¼ N-terminal pro-B-type natriuretic
peptide; other abbreviations as in Table 1.
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257thus, in conditions of ﬂuid overload or exercise, the
subsequent acute elevation of ﬁlling pressures may
lead to reduced diastolic ﬁlling and produce HF
symptoms resulting in hospitalization.
HHF is a growing public health problem. Despite
initial improvement during hospitalization, subse-
quent rehospitalization, morbidity, and mortality
after discharge remain high (18–20). Yet outcomes
have not improved, despite a number of trials with
drugs directed against neurohormonal activity, but
not against targets directly involved in the structural
remodeling of the myocardial collagen matrix (21). In
this conceptual framework, it has been reported that
myocardial extracellular volume fraction (a param-
eter assessed using T1-mapping cardiac magnetic
resonance that closely reﬂects histological diffuse
myocardial ﬁbrosis) is associated with HHF in dia-
betic patients and in patients with nonischemic
dilated cardiomyopathy (22,23). Our ﬁnding that an
excess of CCL in patients with HF of hypertensive
origin, treated as recommended by the guidelines, is
associated with increased risk of HHF adds further
support to the notion that myocardial ﬁbrosis pre-
disposes to HHF in patients with HF of different eti-
ologies. In addition, our ﬁnding points to
mechanisms involved in CCL as potential targets to
treat HF. It must be noted that associations of
enhanced myocardial LOX expression with increased
CCL have been reported in animals with genetic (24)
or induced (25,26) hypertension, as well as in hy-
pertensive patients with HF (27). Furthermore,
addition of torasemide to standard HF therapy in
patients with HF of hypertensive etiology resulted in
normalization of LOX, CCL, and LV chamber stiff-
ness, and improvement of LV function and New York
Heart Association class (27). Of interest, torasemide
has been shown to inhibit bone morphogenetic
protein-1, a protease that activates LOX, in the
myocardium of patients with HF of hypertensive
etiology (28).
ASSOCIATION OF A POTENTIAL BIOMARKER OF CCL
WITH THE RISK OF HHF. Despite its recognition as a
major public health problem in cardiovascular medi-
cine, HHF is difﬁcult to predict (18). Here, we report
that the serum CITP:MMP-1 ratio may be useful as
both a biomarker of abnormally high CCL and a pre-
dictor of HHF (Central Illustration). As shown in the
invasive study, the CITP:MMP-1 ratio fulﬁlls the
criteria proposed for a circulating parameter to be a
biomarker of alterations in myocardial collagen in HF
patients (29). First, it is associated with histologically
determined myocardial CCL and the association is
pathophysiologically coherent. In fact, the higher the
myocardial CCL, the lower the serum CITP:MMP1ratio, suggesting that highly cross-linked collagen
type I ﬁbers are resistant to degradation by MMP-1
(10,12). Secondly, as shown by the ROC curve anal-
ysis, the serum CITP:MMP-1 ratio is a sensitive and
speciﬁc parameter for the identiﬁcation of high
myocardial CCL. Finally, patients with serum
CITP:MMP-1 ratio values #1.968 have a signiﬁcantly
higher probability of presenting with abnormally
high myocardial CCL than patients with serum
CITP:MMP-1 ratios above this value.
In addition, in the noninvasive study we provide
evidence that the serum CITP:MMP-1 ratio is associ-
ated with the risk of presenting with HHF. In fact, HF
patients with serum CITP:MMP-1 ratio values #1.968
have an approximately 2-fold higher probability of
presenting with HHF than patients with a serum
CITP:MMP-1 ratio above this value. It is noteworthy
that the ratio predicts the risk of HHF independent
of several relevant HHF risk factors (19). We also
demonstrate that the serum CITP:MMP-1 ratio
signiﬁcantly increased the basic model’s diagnostic
utility for HHF, as quantiﬁed by the IDI and the
continuous NRI.
STUDY LIMITATIONS. First, because they are
descriptive in nature, the associations found between
myocardial alterations and clinical outcomes in the
invasive study do not establish causality. Secondly,
the limited numbers of events recorded in the same
study constrained risk adjustment and statistical po-
wer, and did not allow us to adjust for every difference
in baseline characteristics. We did adjust for several
clinically-relevant variables encountered in practice,
although we cannot exclude overﬁtting. Thirdly,
we performed biopsies of the right side of the inter-
ventricular septum to assess tissue collagen charac-
teristics. However, as we have shown previously (30),
the septum is representative of the free wall in
the human failing hypertensive heart in terms of
CENTRAL ILLUSTRATION CCL and Hypertensive HF: Identiﬁcation of a Circulating Biomarker of Collagen Type I
Cross-Linking With Prognostic Utility in HF of Hypertensive Origin
López, B. et al. J Am Coll Cardiol. 2016; 67(3):251–60.
In the process of degradation of the collagen type I ﬁber within the myocardial interstitium, the enzyme collagenase or matrix metalloproteinase (MMP)-1
cleaves a small C-terminal telopeptide of the ﬁber or CITP (that represents 1 of the 2 major cross-linking sites in the collagen type I molecule) and a
large N-terminal telopeptide. Because cross-linking between collagen type I molecules determines the resistance of the collagen type I ﬁber to degradation
by MMP-1, the higher the cross-linking, the lower the generation of CITP. Both MMP-1 and CITP reach the systemic circulation and thus can be measured by
speciﬁc enzyme-linked immunosorbent assay methods. We show for the ﬁrst time that a low serum CITP:MMP-1 ratio, determined in blood from the
antecubital vein, identiﬁes patients with high myocardial collagen type I cross-linking and high risk of hospitalization for heart failure (HF) in a population of
patients with HF of hypertensive etiology. Magenta symbols represent cross-links. CCL ¼ collagen cross-linking.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Excessive
myocardial CCL is associated with decompensated systolic and
diastolic heart failure HF in patients with hypertensive heart
disease.
TRANSLATIONAL OUTLOOK: Additional studies are needed
to understand the mechanisms by which disorganization of
collagen ﬁbrils progresses to myocardial ﬁbrosis and deteriora-
tion of ventricular function in patients with HF of hypertensive
etiology and to assess the prognostic value of incorporating
measurements of the ratio of biomarkers of CCL and matrix
metalloproteinase activity in the clinical management of patients
with HF.
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259collagen ﬁber deposition. Fourthly, although in the
noninvasive study we analyzed a larger cohort to
maximize generalizability of the data observed in the
small ﬁrst cohort, our data reﬂect only 1 center’s
experience and cannot be extrapolated to patients
with HF of etiologies other than arterial hypertension.
Furthermore, comorbidities frequently associated
with hypertension (e.g., IHD, DM, stages 3 to 5 CKD)
were absent in the studied populations. Finally,
although HHF carries a signiﬁcantly high mortality
risk (31), we did not ﬁnd an association of CCL with
cardiovascular mortality in the invasive study, or
of the serum CITP:MMP-1 ratio with cardiovascular
mortality in the noninvasive study. However, it
must be mentioned that the rates of cardiovascular
death were low in patients from both the invasive
(3.75 per 100 patients per year) and the noninvasive
(3.86 per 100 patients per year) studies. Still, adju-
dication for cause of death can be challenging,
controversial, and biased.
CONCLUSIONS
For the ﬁrst time, we show that excessive myocardial
CCL identiﬁes those patients with prevalent HF of
hypertensive etiology prone to present with HHF.
Albeit preliminary, our results substantiate the po-
tential usefulness of the serum CITP:MMP-1 ratio to
identify these patients. Furthermore, we demonstrate
that this ratio can add incremental prognostic value,improving the classiﬁcation of patients at risk and
improving model prediction beyond relevant clinical
risk factors.
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